Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.
about
Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operationLassa fever presenting as acute abdomen: a case seriesProgress in the experimental therapy of severe arenaviral infectionsSevere hemorrhagic fever in strain 13/N guinea pigs infected with Lujo virusEffective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic FeverClinical features and patient management of Lujo hemorrhagic feverUse of recombinant adenovirus vectored consensus IFN-α to avert severe arenavirus infectionInhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome.In vitro antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus.Lassa fever - full recovery without ribavarin treatment: a case reportGenomic profiling of host responses to Lassa virus: therapeutic potential from primate to manReplication of boid inclusion body disease-associated arenaviruses is temperature sensitive in both boid and mammalian cellsViruses acquired abroad: what does the primary care physician need to know?A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002-2014: a multicentre retrospective cross-sectional study.Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable - epidemiology, diagnostics and treatment.Ebola and other viral haemorrhagic fevers: a local operational approach.Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria.Efficient rescue of recombinant Lassa virus reveals the influence of S segment noncoding regions on virus replication and virulenceThe High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.Resistance of human plasmacytoid dendritic CAL-1 cells to infection with lymphocytic choriomeningitis virus (LCMV) is caused by restricted virus cell entry, which is overcome by contact of CAL-1 cells with LCMV-infected cells.Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.Lessons learnt from the management of a case of Lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa.Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality.Arenavirus and West Nile virus in solid organ transplantation.Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016.Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis.A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.Lassa fever: another threat from West Africa.Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.Re-emerging Lassa fever outbreaks in Nigeria: Re-enforcing "One Health" community surveillance and emergency response practice.Systematic Review and Meta-analysis of Postexposure Prophylaxis for Crimean-Congo Hemorrhagic Fever Virus among Healthcare WorkersCurrent research for a vaccine against Lassa hemorrhagic fever virusA Case of Lassa Fever Diagnosed at a Community Hospital-Minnesota 2014
P2860
Q21092277-5262D9EA-7C0E-4F47-A369-61A9E833AF4FQ21231955-CDA0C701-DE15-45FB-A74A-334E29063456Q27024953-F7FBDAB2-C733-46F8-B1E8-72DC61585936Q27305359-1EBB64EE-2F07-42F8-82ED-1D47AF4AED07Q28477434-6C8682C7-464B-4F32-B12D-8A7BC5A6B705Q28544917-6C4657AB-51B1-4696-B5F7-ADA1A89D2487Q28743512-32195129-CA25-4F6E-AB33-1E45A4BBDA58Q30429521-16F30191-7526-46DD-97FE-E536B1F9D971Q33409920-8084FCD8-97F2-4D38-89EA-9890905E928FQ33437185-069FE706-E846-4BB7-84E3-9BB9F156C5CAQ35207231-78704411-DED4-4C5D-8BFB-C9E68FB94D66Q35248863-2A24FDDA-5A9C-453A-A107-B1F56F8BCD0AQ35402001-BEAF55EE-9635-4178-A15E-28BB35417297Q36365735-59948901-5DF1-41D9-8F61-3A399F288CA2Q36702610-1641E63F-F309-4082-9F6C-08F8BB90AFBAQ37256780-BC0FD341-EDE4-4FAF-8C05-31A5AD0BC12AQ38016471-2E4F97C9-6EE3-4F8E-9707-51725E966E9DQ38248666-87FA3547-4DC5-4BFC-9E8D-490B010ECF51Q38736159-BA4EE0B5-3959-4FE0-97E3-52363D9A9C09Q39097131-59566B16-75D8-4FEB-8E60-D995B6059D3BQ39388305-62DF7E6E-1E24-4BF4-A294-4CA7F2868910Q39595245-3D45B310-D349-4710-B302-F2921CCDD982Q39602870-45A548A8-FD8E-490F-BF97-9644F7F4F910Q40069302-CECAF632-009C-4BFA-99DF-BBC355E9EB4DQ40092356-29F99283-3A85-44EF-86CE-F5D9D5F53951Q40147436-FA8BBF7F-9C41-4050-A5CD-87CCE528474AQ40156113-6A903B68-36ED-4815-BEDB-FBA71607D7D5Q40237945-EBB6B8ED-B6FD-4F05-BC69-D138FB214BE0Q40255394-7C57E6E2-7669-4E07-BD8D-E68C26CE690DQ41919414-D1846EA7-5CC2-4AF0-AE7D-1A85191095EDQ41929865-821F9A67-3E93-4471-B03F-D9010A7D37DCQ46251489-68B92B45-F64C-4EA6-AE34-7E37906FDF53Q46768300-20D958E6-8368-46CA-8234-9EB8A1AF97E8Q51333133-B4FA4977-63FD-4FF9-A289-703341B3ECAFQ52590886-2E19FB30-0309-4B27-AB22-5ED7537ED4FAQ52723914-B7B60924-D8ED-4F9B-BB5D-23B85C9D9787Q55188128-7CD34F07-71DE-4132-9D7C-3763DB0927A3Q56395333-D6C92E29-83B8-4C5B-AF73-1DA6E2B67792Q56909960-2370317D-790E-442A-8E8B-7190F202CDFCQ57002447-0C51ADCA-2395-46B3-B7E4-3A13FD64C250
P2860
Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Review of the literature and p ...... e prophylaxis for Lassa fever.
@ast
Review of the literature and p ...... e prophylaxis for Lassa fever.
@en
Review of the literature and p ...... e prophylaxis for Lassa fever.
@nl
type
label
Review of the literature and p ...... e prophylaxis for Lassa fever.
@ast
Review of the literature and p ...... e prophylaxis for Lassa fever.
@en
Review of the literature and p ...... e prophylaxis for Lassa fever.
@nl
prefLabel
Review of the literature and p ...... e prophylaxis for Lassa fever.
@ast
Review of the literature and p ...... e prophylaxis for Lassa fever.
@en
Review of the literature and p ...... e prophylaxis for Lassa fever.
@nl
P2093
P356
P1476
Review of the literature and p ...... e prophylaxis for Lassa fever.
@en
P2093
Christiane M Hadi
Daniel G Bausch
Juan J L Lertora
Sheik Humarr Khan
P304
P356
10.1086/657315
P407
P577
2010-11-08T00:00:00Z